Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis
A randomized, open-label, parallel-group, non-inferiority study comparing efficacy, safety, and tolerability of remibrutinib after switching from ocrelizumab in participants living with relapsing multiple sclerosis, followed by open-label treatment with remibrutinib
-
Clinical Trial Information
Trial Contact: Carlo, Charlene S; Monserrate, Francheska; Melendez, Thomas L; Mondragon, Diana
Trial Phone: 321.841.1324 ; 321-830-7617 ; 321.841.6813 ; 3218414717
-
IRB No: S25.039.02
Protocol Abbrev: RESHAPE
Principal Investigator: Amy (Amparo) Gutierrez, MD, FAAN
Phase: Drug: Phase III
Age Group: Adult
Secondary Protocol No: CLOU064C12306
Treatment: remibrutinib and ocrelizumab
Therapies Involved: Medication
ClinicalTrials.gov ID: NCT# 06846281
-
Objective
To demonstrate that remibrutinib is non-inferior to ocrelizumab in controlling inflammatory activity on magnetic resonance imaging (MRI) after switching from ocrelizumab.
-
Key Eligibility
over 40 with relapsing multiple sclerosis on ocrelizumab
